What is epitalon, and is it spelled epithalon?

Both spellings refer to the same compound, a tetrapeptide with the sequence Ala-Glu-Asp-Gly, and you will encounter it written as epitalon, epithalon and occasionally epithalamin. It is the best-known of the peptide bioregulators and is associated with research on the pineal gland in the literature from the group that developed it. Four residues makes it a very small molecule by any standard.

What are pinealon and vilon?

Both are shorter still. Pinealon is a tripeptide, Glu-Asp-Arg, and vilon is a dipeptide, Lys-Glu. They come from the same research programme as epitalon and are discussed in the same framework, with each associated in that literature with a particular tissue or system. Vilon at two residues is about as short as a peptide can be and still be called one.

What is the proposed mechanism?

The literature from this research programme proposes that very short peptides can interact directly with DNA and influence gene expression, which is the mechanism offered for how molecules of this size could have the broad effects described. It is worth recognising that this is a strong claim. Sequence-specific DNA recognition is normally the province of proteins with substantial structured binding domains, and a two-to-four-residue peptide has very little structure to work with.

How strong is the evidence for peptide bioregulators?

This is the most important question about them and the answer requires care. The great majority of published work comes from a single research institute in St Petersburg and its collaborators, much of it is published in Russian-language or low-visibility journals, and independent replication by unconnected international groups is very limited. A body of evidence concentrated in one group is weaker than the same number of papers spread across many, because independent replication is the mechanism by which findings are tested. That does not make the work wrong, but it does mean confidence should be held loosely.

Are peptide bioregulators approved medicines?

None of them holds a marketing authorisation in the UK. Regulatory history differs between compounds and jurisdictions, and some have had a different status within Russia, but in the UK they are not licensed medicines and cannot lawfully be supplied for human medicinal use. Material sold under these names is supplied for in-vitro laboratory research only.

Do you sell epitalon, pinealon or vilon?

No. We stock none of them and there are no Certificates of Analysis for them in our library. They are documented here because they generate steady search interest and the available information rarely mentions the limitations of the evidence base, which is the thing a reader most needs to know.

What are peptide bioregulators?

7 min read · Updated October 2026 · MY PEPTIDES Research Team

Key facts

Peptide bioregulators are a family of very short peptides, typically two to four amino acids, associated with research conducted at the St Petersburg Institute of Bioregulation and Gerontology in Russia. The best known are epitalon, also spelled epithalon, with the sequence Ala-Glu-Asp-Gly; pinealon, Glu-Asp-Arg; and vilon, Lys-Glu. The proposed mechanism in that literature is that such short peptides can interact with DNA and influence gene expression, which is a strong claim for molecules of this size. The important caveat is the structure of the evidence: the great majority of published work originates from a single research institute and its collaborators, much of it appears in Russian-language or low-visibility journals, and independent international replication is very limited. None of these compounds holds a marketing authorisation in the UK. MY PEPTIDES does not stock any of them. General information for laboratory context only, not medical advice.

The short answer

Peptide bioregulators are a family of very short peptides, two to four amino acids long, from a single line of research conducted at the St Petersburg Institute of Bioregulation and Gerontology.

The three most searched are epitalon, also spelled epithalon, a tetrapeptide of Ala-Glu-Asp-Gly; pinealon, a tripeptide of Glu-Asp-Arg; and vilon, a dipeptide of Lys-Glu.

They are discussed here with more caution than most compounds on this site, and the reason is not the chemistry. It is the structure of the evidence behind them, which is unusual and which almost no page selling them mentions.

What they are, structurally

These are about as small as peptides get. Vilon has a single peptide bond. Epitalon has three. At that size there is essentially no secondary structure, no folding, no binding pocket, nothing that would normally be described as a three-dimensional shape beyond the rotational freedom of a very short chain.

Their synthesis is correspondingly trivial and their analysis straightforward: a tetrapeptide elutes cleanly and gives an unambiguous mass, so there is little room for a certificate to be vague. If you were assessing documentation for one of these, the questions in our guide on certificates of analysis should be easy for any competent supplier to answer.

The mechanism claim, and why it deserves scrutiny

The proposal in this literature is that peptides of this size interact directly with DNA and influence gene expression. That is what has to be true for molecules this small to produce the breadth of effects described for them.

It is worth sitting with how strong that claim is. Sequence-specific DNA recognition in well-characterised biology is carried out by proteins with substantial structured binding domains: transcription factors, with folded motifs that read the double helix across several base pairs. A dipeptide has two residues and one bond. Proposing that it achieves comparable specificity is not impossible in principle, but it is a significant departure from the established picture, and claims that depart significantly from established mechanism need correspondingly strong evidence.

That is the standard any reader should apply, and it is the standard that makes the next section the important one.

The evidence problem

Most of what is published about peptide bioregulators originates from one research institute and the collaborators around it. Much of it appears in Russian-language journals or in publications with limited international visibility. Independent replication by unconnected groups is very limited.

This matters structurally rather than nationally, and the point is not about where the work was done. Independent replication is the mechanism by which science tests itself. A finding reproduced by groups with no shared assumptions, no shared reagent supply, no shared methods and no shared stake in the outcome has survived a test that the same finding repeated within one programme has not faced. Fifty papers from one institute are weaker evidence than five from five.

So the honest summary is this: there is a substantial published literature, and it is concentrated in a way that limits how much weight it can bear. A reader who takes the volume of papers as the measure of confidence will overestimate what is known. That is true regardless of whether the underlying findings eventually hold up.

You will not generally find this said on pages selling these compounds, which is most of what a search returns.

What that means in practice

For laboratory use, these are cheap, simple, easily characterised peptides, and studying them is perfectly reasonable. Anyone can test a short peptide in their own system and see what happens.

What the evidence does not support is confident extrapolation. None of these compounds holds a marketing authorisation in the UK, none has the independent clinical evidence base that would justify claims about human outcomes, and anti-ageing framing in particular runs far ahead of what the published work can carry. Supplying an unlicensed product for human medicinal use is unlawful under the Human Medicines Regulations 2012 however a listing is phrased, and our guide on whether peptides are legal in the UK covers the framework.

Where MY PEPTIDES stands

We do not stock epitalon, pinealon or vilon. There are no Certificates of Analysis for them in our library, no product pages for them on this site, and this guide is not an offer to supply them.

We have written it the way we have because the alternative, on current evidence, would be to repeat claims we cannot stand behind. If that reads as unenthusiastic for a page on a supplier's website, that is the honest position rather than a commercial one.

The bottom line

Epitalon, pinealon and vilon are very short peptides from a single line of Russian gerontology research, proposed to act by interacting directly with DNA. They are simple molecules and easy to characterise. The evidence for what is claimed about them is concentrated in one research programme with little independent replication, which is the most important thing to know and the thing least often said. None is a UK-licensed medicine and we supply none of them.

All compounds referenced on this site are discussed strictly in the context of in-vitro laboratory research. Nothing here is a medicine, a supplement or a therapeutic product, nothing here describes administration to humans or animals, and this guide is general information rather than medical, legal or research advice.

Frequently asked questions

What is epitalon, and is it spelled epithalon?: Both spellings refer to the same compound, a tetrapeptide with the sequence Ala-Glu-Asp-Gly, and you will encounter it written as epitalon, epithalon and occasionally epithalamin. It is the best-known of the peptide bioregulators and is associated with research on the pineal gland in the literature from the group that developed it. Four residues makes it a very small molecule by any standard.
What are pinealon and vilon?: Both are shorter still. Pinealon is a tripeptide, Glu-Asp-Arg, and vilon is a dipeptide, Lys-Glu. They come from the same research programme as epitalon and are discussed in the same framework, with each associated in that literature with a particular tissue or system. Vilon at two residues is about as short as a peptide can be and still be called one.
What is the proposed mechanism?: The literature from this research programme proposes that very short peptides can interact directly with DNA and influence gene expression, which is the mechanism offered for how molecules of this size could have the broad effects described. It is worth recognising that this is a strong claim. Sequence-specific DNA recognition is normally the province of proteins with substantial structured binding domains, and a two-to-four-residue peptide has very little structure to work with.
How strong is the evidence for peptide bioregulators?: This is the most important question about them and the answer requires care. The great majority of published work comes from a single research institute in St Petersburg and its collaborators, much of it is published in Russian-language or low-visibility journals, and independent replication by unconnected international groups is very limited. A body of evidence concentrated in one group is weaker than the same number of papers spread across many, because independent replication is the mechanism by which findings are tested. That does not make the work wrong, but it does mean confidence should be held loosely.
Are peptide bioregulators approved medicines?: None of them holds a marketing authorisation in the UK. Regulatory history differs between compounds and jurisdictions, and some have had a different status within Russia, but in the UK they are not licensed medicines and cannot lawfully be supplied for human medicinal use. Material sold under these names is supplied for in-vitro laboratory research only.
Do you sell epitalon, pinealon or vilon?: No. We stock none of them and there are no Certificates of Analysis for them in our library. They are documented here because they generate steady search interest and the available information rarely mentions the limitations of the evidence base, which is the thing a reader most needs to know.